Stay updated on PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial page.

Latest updates to the PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedRevision v3.3.4 was added and Revision v3.3.3 was removed; this is a routine page update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check29 days agoChange DetectedThe study's location information was reorganized: a consolidated 'Locations' section was added, and the per-state subsections for California, Louisiana, New York, Ohio, and Texas were removed (revision v3.3.3).SummaryDifference0.7%

- Check58 days agoChange DetectedThe page footer now shows Revision: v3.3.2, replacing Revision: v3.2.0.SummaryDifference0.1%

- Check65 days agoChange DetectedDeleted the funding/operating-status notice banner at the top of the study record page; the remaining study content is unchanged.SummaryDifference0.4%

- Check79 days agoChange DetectedNo significant changes to core content were detected; the updates appear to be minor editorial or formatting changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check108 days agoChange DetectedMajor change: page now carries a government-operating-status notice and a new version tag (v3.2.0) replacing the old one (v3.1.0).SummaryDifference3%

Stay in the know with updates to PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial page.